BioGaia AB's EBIT per Share for the
three
months ended in Mar. 2026 was $0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.45.
During the past 12 months, the average EBIT per Share Growth Rate of BioGaia AB was 10.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 10.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 13.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioGaia AB's EBIT per Share or its related term are showing as below:
BGLAF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -58.9 Med: 13.85 Max: 192.6
Current: 10.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BioGaia AB was 192.60% per year. The lowest was -58.90% per year. And the median was 13.85% per year.
BGLAF's 3-Year EBIT Growth Rate is ranked better than 54.21% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs BGLAF: 10.50
BioGaia AB's EBIT for the
three
months ended in Mar. 2026 was $11.1 Mil.
BioGaia AB (OTCPK:BGLAF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioGaia AB EBIT per Share Related Terms
BioGaia AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for BioGaia AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a EBIT per Share of $0.45 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioGaia AB and its competitors. According to the industry distribution chart, BioGaia AB ranks #370 out of 808 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is BioGaia AB's EBIT per Share too high?
BioGaia AB's current EBIT per Share is $0.45. The Drug Manufacturers industry median EBIT per Share is 7.65. BioGaia AB's value of $0.45 is 94.1% below this industry median. Based on the distribution chart, BioGaia AB ranks #370 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #370 out of 808 companies for EBIT per Share. This puts BioGaia AB in the upper half of its industry. The industry median EBIT per Share is 7.65. BioGaia AB's value of $0.45 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current EBIT per Share of $0.45 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current EBIT per Share is $0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current EBIT per Share of $0.45. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current EBIT per Share is $0.45 and 94.1% below the Drug Manufacturers industry median of 7.65. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current EBIT per Share is $0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
EBIT per Share: $0.45
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 94.1% below the Drug Manufacturers median (#370 of 808)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
